Hypothetical phone call" Hi Jim, its Ian Read..how are things going, hows the wife and kids. Its been almost a year since we had to shut down our AD research and move almost 300 of our valued mambers of our company. You know I have alot of of respect for your work and abilities and you know it was a board decision .. we just could not justify spending so much money and not get the results we needed. "
" Thanks Ian. I understand the business of pharmas and the demands put on you by the board and major shareholders. I am doing really good but it sure is nice to be back doing what I really enjoy "
" So Jim, I was rather surprised to see you jump on board an unknown and unproven small cap company, thats just not your style."
" Ian , I never would have thought I would want to have anything to do with a company thats not even big enough to be called a pimple, but I got to tell you something .. these guys are onto to something like I have never seen before"
" Oh come on Jim .. what could they have that we have not seen before"
" Well you know that we always were competing with the Biogen crew and we realized that last year they were having really good results with the Aducanumab and just last month they showed some stability with their BAN2401. Well this smalll company has found ways to get around a few of the concerns that Biogen has and I think they have found a way to make their line of anitbodies even more target specfic then anyone else. I had to go over their data three or four times because I just didnt think it was possible to do what they say they can do. The PMN310 that they have developed is like nothing I have seen before. If we would have had this science and approach when we were doing AD work , I think we would have had the best product out there. "
" Hold it Jim, are you saying that they are going to overtake Biogen when this all comes to fruition"
" Yes Ian and that is why I really wanted to be a part of this. These guys are going to be able to generate results that will blow everyones minds. Everyone is stuck at adminstrating doses of 10mgs to 1 kg , and thats because they cant get around the bleeding to the brain. For Christs sakes these guys are planning on dosing upto 40 mgs. Their data shows that their line only attaches to the oligomor and not to the plaque or monimer, like we had problems. I checked it out, the data validates their claim"
" Well Jim you sound very excited abouit this .. would this be something that Phizer should be watching closely, we would reallyn like to get back into the AD development, it has an incredible market waiting world wide"
YES Ian ... I think Phizer should watch these guys very closely. I think you should get hold of Gene and Elliott and make it known that you are interested in their AD development. They have a really impressive data room set up in Boston and I know that alot of your competitors have been in there going over the data they have. You will be impressed when they JV their PD and ALS porgrams later this year . Its the same principal .. they can succesfully target a specfic part of a cell and they seem to have the ability to do it for a wide range of diseases.
" Jim its been really nice talking to you and I think that what I have heard from you is very interesting. Are you OK if we talk again , I may need to pick your brain , even though you are no longer with Phizer. We will talk soon. Stay in touch. "
* Disclaimer " If this was a book it would be in the fiction section of the book store **